As Sage Therapeutics Inc. contemplates its path forward after rejecting a buyout offer from Biogen, its top executive ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics, listed on The Nasdaq Global ... Meanwhile, Mizuho Securities raised its price target for Sage to $9, following Biogen (NASDAQ:BIIB)’s proposal to acquire the company.

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Investors and stakeholders of Sage Therapeutics will be watching closely as the company ... Meanwhile, Mizuho Securities raised its price target for Sage to $9, following Biogen (NASDAQ:BIIB)’s ...

US-based Praxis Precision has decided not to halt its Phase III trial examining its essential tremor (ET) therapy after an ...

Cambridge, MA-based Sage Therapeutics, Inc. has announced the resignation of ... Meanwhile, Mizuho Securities raised its price target for Sage to $9, following Biogen (NASDAQ:BIIB)’s proposal to ...

Sage Therapeutics (SAGE) announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the ...

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...